Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies

Best Practice and Research: Clinical Rheumatology

Volumn 31, Issue 4, 2017, Pages 505-516

  Pardeo, Manuela ^a   Bracaglia, Claudia ^a   De Benedetti, Fabrizio ^a  

^a 4University of Roma la Sapienza   (Italy)

Author keywords

Autoinflammatory disease; IFN ; IL 1; IL 18; IL 6; Macrophage activation syndrome; Systemic juvenile idiopathic arthritis

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 1; INTERLEUKIN 1 INHIBITOR; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 6 INHIBITOR; PROTEIN S 100; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; MACROPHAGE ACTIVATION SYNDROME; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOMARKERS; CYTOKINES; HUMANS; IMMUNITY, INNATE; MACROPHAGE ACTIVATION SYNDROME;

EID: 85044152580     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2018.02.002     Document Type: Review

References (86)

1. Ravelli, A., Martini, A., Juvenile idiopathic arthritis. Lancet 369 (2007), 767–778.
2. Masters, S.L., Simon, A., Aksentijevich, I., Kastner, D.L., Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 27 (2009), 621–628.
3. Cassidy, J.T., Petty, R.E., Textbook of pediatric rheumatology. 7th ed., 2015, Elsevier, St. Louis.
4. Martini, A., Systemic juvenile idiopathic arthritis. Autoimmun Rev 12 (2012), 56–59.
5. Hedrich, C.M., Tsokos, D.L., Bridging the gap between autoinflammation and autoimmunity. Clin Immunol 147 (2013), 151–154.
6. Ravelli, A., Grom, A.A., Behrens, E.M., Cron, R.Q., Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun 13:4 (2012), 289–298.
7. Behrens, E.M., Beukelman, T., Paessler, M., Cron, R.Q., Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34 (2007), 1133–1138.
8. Petty, R.E., Southwood, T.R., Manners, P., Baum, J., Glass, D.N., Goldenberg J, J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31 (2004), 390–392.
9. Schneider, R., Laxer, R.M., Systemic onset juvenile rheumatoid arthritis. Bailliere's Clin Rheumatol 12 (1998), 245–271.
10. Lang, B.A., Schneider, R., Reilly, B.J., Silverman, E.D., Laxer, R.M., Radiologic features of systemic onset juvenile rheumatoid arthritis. J Rheumatol 22 (1995), 168–173.
11. Martini, A., It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis 71 (2012), 1437–1439.
12. Ogilvie, E.M., Fife, M.S., Thompson, S.D., Twine, N., Tsoras, M., Moroldo, M., et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 48 (2003), 3202–3206.
13. De Benedetti, F., Meazza, C., Vivarelli, M., Rossi, F., Pistorio, A., Lamb, R., et al. British Paediatric Rheumatology Study Group. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 48 (2003), 1398–1407.
14. Stock, C.J., Ogilvie, E.M., Samuel, J.M., Fife, M., Lewis, C.M., Woo, P., Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes Immun 9 (2008), 349–357.
15. Ombrello, M.J., Remmers, E.F., Tachmazidou, I., Grom, A.A., Foell, D., Haas, J.P., et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc Natl Acad Sci USA 112 (2015), 15970–15975.
16. Ombrello, M.J., Arthur, V.L., Remmers, E.F., Hinks, A., Tachmazidou, I., Grom, A.A., et al. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis 76 (2017), 906–913.
17. Barnes, M.G., Grom, A.A., Thompson, S.D., Griffin, T.A., Pavlidis, P., Itert, L., et al. Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiophathic arthritis. Arthritis Rheum 6D (2009), 2102–2112.
18. Allantz, F., Chaussabel, D., Stichweh, D., Bennett, L., Allman, W., Mejias, A., et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 204:9 (2007), 2131–2144.
19. Ishikawa, S., Mima, T., Aoki, C., Yoshio-Hoshino, N., Adachi, Y., Imagawa T, T., et al. Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis. Ann Rheum Dis 68 (2009), 264–272.
20. Mellins, E.D., Macaubas, C., Grom, A.A., Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 7 (2011), 416–426.
21. Sandborg, C., Mellins, E.D., A new era in the treatment of systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2430–2440.
22. Pascual, V., Allantz, F., Arce, E., Punaro, M., Banchereau, J., Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201 (2005), 1479–1486.
23. Dinarello, C.A., Biologic basis for interleukin-1 in disease. Blood 87 (1996), 2095–2147.
24. Cazzola, M., Ponchio, L., de Benedetti, F., Ravelli, A., Rosti, V., Beguin, Y., et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87 (1996), 4824–4830.
25. PRINTO; PRCSGRuperto, N., Brunner, H.I., Quartier, P., Constantin, P., Wulffrat, N., Horneff, G., et al. Two randomized trials of Canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2396–2406.
26. De Benedetti, F., Massa, M., Robbioni, P., Ravelli, A., Burgio, G.R., Martini, A., Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34 (1991), 1158–1163.
27. De Benedetti, F., Alonzi, T., Moretta, A., Lazzaro, D., Costa, P., Poli, V., et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. J Clin Invest 99 (1997), 643–650.
28. De Benedetti, F., Rucci, N., Del Fattore, A., Peruzzi, B., Paro, R., Longo, M., et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 54 (2006), 3551–3563.
29. Caiello, I., Minnone, G., Holzinger, D., Vogl, T., Prencipe, G., Manzo, A., et al. IL-6 amplifies TLR mediated cytokine and chemokine production: implications for the pathogenesis of rheumatic inflammatory diseases. PLoS One, 9, 2014, e107886.
30. PRINTO; PRCSGDe Benedetti, F., Brunner, H.I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367 (2012), 2385–2395.
31. Kessel, C., Holzinger, D., Foell, D., Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunol 147 (2013), 229–241.
32. Vogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M.A., et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13 (2007), 1042–1049.
33. Frosch, M., Ahlmann, M., Vogl, T., Wittkowski, H., Wulffraat, N., Foell, D., et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60 (2009), 883–891.
34. Swart, J.F., de Rook, S., Prakken, B.J., Understanding inflammation in juvenile idiopathic arthritis: How immune biomarkers guide clinical strategies in the systemic onset subtype. Eur J Immunol 46 (2016), 2068–2077.
35. Holzinger, D., Frosch, M., Kastrup, A., Prince, F.H., Otten, M.H., Van Suijlekom-Smit, L.W., et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 71 (2012), 974–980.
36. Okamura, H., Nagata, K., Komatsu, T., Tanimoto, T., Nukata, Y., Tanabe, F., et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 63 (1995), 3966–3972.
37. Okamura, H., Tsutsi, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., et al. Cloning of a new cytokine that induces IFN-g production by T cells. Nature 378 (1995), 88–91.
38. Novick, D., Kim, S., Kaplanski, G., Dinarello, C.A., Interleukin-18, more than a Th1 cytokine. Semin Immunol 25 (2013), 439–448.
39. Leung, B.P., Culshaw, S., Gracie, J.A., Hunter, D., Canetti, C.A., Campbell, C., et al. A role for IL-18 in neutrophil activation. J Immunol 167 (2001), 2879–2886.
40. Maeno, N., Takei, S., Nomura, Y., Imanaka, H., Hokonohara, M., Miyata, K., Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima, et al. Arthritis Rheum 46 (2002), 2539–2541.
41. Shimizu, M., Nakagishi, Y., Yachie, A., Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 61 (2013), 345–348.
42. Jelusić M., Lukić I.K., Tambić-Bukovac, L., Dubravcić K., Malcić I., Rudan, I., et al. Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis. Clin Rheumatol 26 (2007), 1332–1334.
43. Shimizu, M., Nakagishi, Y., Inoue, N., Mizuta, M., Ko, G., Saikawa, Y., et al. Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Clin Immunol 160 (2015), 277–281.
44. Bracaglia, C., Pires Marafon, D., Caiello, I., de Graaf, K., Ballabio, M., Ferlin, W., et al. Biomarkers for the diagnosis and the identification of risk of macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis (sJIA). [abstract]. Arthritis Rheumatol, 69(Suppl. 10), 2017.
45. Canna, S.W., de Jesus, A.A., Gouni, S., Brooks, S.R., Marrero, B., Liu, Y., et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46 (2014), 1140–1146.
46. Romberg, N., Al Moussawi, K., Nelson-Williams, C., Stiegler, A.L., Loring, E., Choi, M., et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 46 (2014), 1135–1139.
47. Grom, A.A., Villanueva, J., Lee, S., Goldmuntz, E.A., Passo, M.H., Filipovich, A., Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 142 (2003), 292–296.
48. Cifaldi, L., Prencipe, G., Caiello, I., Bracaglia, C., Locatelli, F., De Benedetti, F., et al. Inhibition of natural killer (nk) cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Pediatr Rheumatol, 12(Suppl. 1), 2014, 56.
49. de Jager, W., Vastert, S.J., Beekman, J.M., Wulffraat, N.M., Kuis, W., Coffer, P.J., et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 60 (2009), 2782–2793.
50. Kaufman, K.M., Linghu, B., Szustakowski, J.D., Husami, A., Yang, F., Zhang, K., et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 66 (2014), 3486–3495.
51. Vastert, S.J., van Wijk, R., D'Urbano, L.E., de Vooght, K.M., de Jager, W., Ravelli, A., et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) 49 (2010), 441–449.
52. Zhang, K., Biroschak, J., Glass, D.N., Thompson, S.D., Finkel, T., Passo, M.H., et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum 58 (2008), 2892–2896.
53. Hazen, M.M., Woodward, A.L., Hofmann, I., Degar, B.A., Grom, A., Filipovich, A.H., et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 58 (2008), 567–570.
54. Bracaglia, C., Sieni, E., Da Ros, M., De Fusco, C., Micalizzi, C., Cetica, V., et al. Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J, 12(Suppl. 1), 2014, 53.
55. Strippoli, R., Caiello, I., De Benedetti, F., Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. J Rheumatol 40 (2013), 761–767.
56. Boom, V., Anton, J., Lahdenne, P., Quartier, P., Ravelli, A., Wulffraat, N.M., et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J, 13, 2015, 55.
57. Nigrovic, P.A., Mannion, M., Prince, F.H., Zeft, A., Rabinovich, C.E., van Rossum, M.A., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63 (2011), 545–555.
58. Grom, A.A., Ilowite, N.T., Pascual, V., Brunner, H.I., Martini, A., Lovell D, D., et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol 68 (2016), 218–228.
59. Ravelli, A., Schneider, R., Weitzman, S., et al. A56: macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Arthritis Rheumatol, 2014, S83–S84.
60. Yokota, S., Itoh, Y., Morio, T., Sumitomo, N., Daimaru, K., Minota, S., Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol 42 (2015), 712–722.
61. Jordan, M.B., Hildeman, D., Kappler, J., Marrack, P., An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104 (2004), 735–743.
62. Pachlopnik Schmid, J., Ho, C.-H., Chretien, F., Lefebvre, J.M., Pivert, G., Kosco-Vilbois, M., et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 1 (2009), 112–124.
63. Takada, H., Takahata, Y., Nomura, A., Ohga, S., Mizuno, Y., Hara, T., Increased serum levels of interferongamma-iinducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin Exp Immunol 133 (2003), 448–453.
64. Xu, X.-J., Tang, Y.-M., Song, H., Yang, S.L., Xu, W.Q., Zhao, N., et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr 160 (2012), 984–990.
65. Bracaglia, C., de Graaf, K., Pires Marafon, D., Guilhot, F., Ferlin, W., Prencipe, G., et al. Elevated circulating levels of interferon-γ and interferon-γ induced chemokines characterize patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis 76 (2017), 166–172.
66. Prencipe, G., Caiello, I., Pascarella, A., Grom, A.A., Bracaglia, C., Chatel, L., et al. Neutralization of IFN-γ reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol 12 (2017), S0091–S6749 (17)31277-0.
67. Quartier, P., Allantaz, F., Cimaz, R., Pillet, P., Messiaen, C., Bardin, C., et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 70 (2011), 747–754.
68. Ilowite, N.T., Prather, K., Lokhnygina, Y., Schanberg, L.E., Elder, M., Milojevic, D., et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 66 (2014), 2570–2579.
69. Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371 (2008), 998–1006.
70. Vastert, S.J., de Jager, W., Noordman, B.J., Holzinger, D., Kuis, W., Prakken, B.J., et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol 66 (2014), 1034–1043.
71. Pardeo, M., Pires Marafon, D., Insalaco, A., Bracaglia, C., Nicolai, R., Messia, V., et al. Anakinra in systemic juvenile idiopathic arthritis: a single-center experience. J Rheumatol 42 (2015), 1523–1527.
72. Gattorno, M., Piccini, A., Lasigliè D., Tassi, S., Brisca, G., Carta, S., et al. A. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58 (2008), 1505–1515.
73. Lequerré T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., et al. Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67 (2008), 302–308.
74. Verbsky, J.W., White, A.J., Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31 (2004), 2071–2075.
75. Urien, S., Bardin, C., Bader-Meunier, B., Mouy, R., Compeyrot-Lacassagne, S., Foissac, F., et al. Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoimflammatory syndromes. BMC Pharmacol and Toxicol, 14, 2013, 40.
76. Yokota, S., Itoh, Y., Morio, T., Origasa, H., Sumitomo, N., Tomobe, M., et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 75:9 (2016 Sep), 1654–1660.
77. Grom, A.A., Horne, A., De Benedetti, F., Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12 (2016), 259–268.
78. Schulert, G.S., Minoia, F., Bohnsack, J., Cron, R.Q., Hashad, S., KonÉ-Paut, I., et al. Biologic therapy modifies clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken), 2017 May 12, 10.1002/acr.23277.
79. Ravelli, A., Minoia, F., Davì S., Horne, A., Bovis, F., Pistorio, A., et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League against Rheumatism/American College of Rheumatology/Paediatric Rheumatology international trials Organisation Collaborative initiative. Ann Rheum Dis 75 (2016), 481–489.
80. DeWitt, E.M., Kimura, Y., Beukelman, T., Nigrovic, P.A., Onel, K., Prahalad, S., et al. Juvenile idiopathic arthritis disease-specific research committee of childhood arthritis rheumatology and research alliance. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 64 (2012), 1001–1010.
81. Ringold, S., Weiss, P.F., Beukelman, T., Dewitt, E.M., Ilowite, N.T., Kimura, Y., et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res 65 (2013), 1551–1563.
82. Nigrovic, P.A., Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?. Arthritis Rheumatol 66 (2014), 1405–1413.
83. Tarp, S., Amarilyo, G., Foeldvari, I., Christensen, R., Woo, J.M., Cohen, N., et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology 554 (2016), 669–679.
84. Kessel, C., Lippitz, K., Weinhage, T., Hinze, C., Wittkowski, H., Holzinger, D., et al. Proinflammatory cytokine environments can drive Interleukin-17 overexpression by γ/δ T cells in systemic juvenile idiopathic arthritis. Arthritis Rheumatol 69 (2017), 1480–1494.
85. Jordan, M.B., Locatelli, F., Allen, C., De Benedetti, F., Grom, A., Ballabio, M., et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot Phase 2 study in children with primary HLH. Blood, 126, 2015 LBA-3.
86. Bracaglia, C., Prencipe, G., Gatto, A., Pardeo, M., Lapeyre, G., Raganelli, L., et al. Anti-interferon-gamma (IFNγ) monoclonal antibody treatment in a child with NLRC4-related disease and severe hemophagocytic lymphohistiocytosis (HLH). [abstract 2433]. Arthritis Rheumatol, 67(Suppl. 10), 2015.